After the FDA delayed the approval of MDMA-assisted therapy for PTSD, there’s still a way forward for psychedelic medicines, experts said at HLTH.
The post What’s Next for Psychedelic Medicines? appeared first on MedCity News.
Related Articles
Should Dynamic Drug Pricing be Incorporated into Cost-Effectiveness Analyses?
Cost effectiveness analyses (CEA) aim to examine how a new health technologies...
5 Interesting Companies I Saw at HLTH
I met a mix of biotech and healthtech companies at HLTH affecting...
Patty Hayward, TalkDesk
Patty Hayward is GM of Healthcare and Life Sciences at TalkDesk. TalkDesk...
How chatbots are enhancing patient care
Consumers have come to expect options when communicating with the companies they...
Leave a comment